About Gamma-butyrobetaine dioxygenase
Gamma-butyrobetaine dioxygenase (BBOX1) is a protein
from Homo sapiens identified by UniProt accession
O75936, 387 residues long.
MolForge cross-references it against 0 known binders and
146 disease associations.
Target properties
| Protein name | Gamma-butyrobetaine dioxygenase |
| UniProt accession | O75936 |
| Gene | BBOX1 |
| Organism | Homo sapiens |
| Length | 387 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (146)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.42
- appendicular lean mass · score 0.40
- body fat percentage · score 0.36
- neurodegenerative disease · score 0.28
- heel bone mineral density · score 0.12
- hepatocellular carcinoma · score 0.10
- neoplasm · score 0.08
- gonorrhea · score 0.08
- non-small cell lung carcinoma · score 0.08
- oral squamous cell carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75936-F1 | alphafold | PREDICTED | 94.86 | — |
Amino-acid sequence (387 residues)
MACTIQKAEA LDGAHLMQIL WYDEEESLYP AVWLRDNCPC SDCYLDSAKA RKLLVEALDV NIGIKGLIFD RKKVYITWPD EHYSEFQADW LKKRCFSKQA RAKLQRELFF PECQYWGSEL QLPTLDFEDV LRYDEHAYKW LSTLKKVGIV RLTGASDKPG EVSKLGKRMG FLYLTFYGHT WQVQDKIDAN NVAYTTGKLS FHTDYPALHH PPGVQLLHCI KQTVTGGDSE IVDGFNVCQK LKKNNPQAFQ ILSSTFVDFT DIGVDYCDFS VQSKHKIIEL DDKGQVVRIN FNNATRDTIF DVPVERVQPF YAALKEFVDL MNSKESKFTF KMNPGDVITF DNWRLLHGRR SYEAGTEISR HLEGAYADWD VVMSRLRILR QRVENGN
Explore Gamma-butyrobetaine dioxygenase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets